Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9HDD0
UPID:
PLAT1_HUMAN
Alternative names:
HRAS-like suppressor 1; Phospholipid-metabolizing enzyme A-C1
Alternative UPACC:
Q9HDD0; D2KX19; Q6X7C0; Q86WS9; X6R3D1
Background:
Phospholipase A and acyltransferase 1, also known as HRAS-like suppressor 1 and Phospholipid-metabolizing enzyme A-C1, plays a crucial role in lipid metabolism. It exhibits phospholipase A1/2 and acyltransferase activities, catalyzing the release of fatty acids from glycerophospholipids and transferring fatty acyl groups among lipids. This protein's ability to modify phospholipids suggests its importance in cellular processes.
Therapeutic significance:
Understanding the role of Phospholipase A and acyltransferase 1 could open doors to potential therapeutic strategies. Its involvement in lipid metabolism and modification makes it a promising target for drug discovery, aiming to regulate lipid-related disorders.